Clinical trials: Central Nervous System Bacterial Infections
AIDS-Related Opportunistic Infections, Meningo-encephalitis
Driving Reduced AIDS-associated Meningo-encephalitis Mortality
The DREAMM project is investigating whether the DREAMM interventions (1) Health system strengthening, 2) Co-designed education programs tailored to frontline healthcare workers, 3) Implementation of a diagnostic and treatment…
- Conditions
- AIDS-Related Opportunistic Infections, Meningo-encephalitis, Cryptococcal Meningitis, Bacterial Meningitis
- Trial name
- DREAMM (NCT03226379)
- Testing
- DREAMM
- Where
- 5 sites in Cameroon, Malawi and 1 more
- Volunteers
- 495 people
- Sponsor
- St George's, University of London
Meningitis, Cryptococcal, HIV Infections
A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.
To evaluate and estimate the safety and efficacy of the combination of fluconazole and flucytosine as treatment for acute cryptococcal meningitis in patients with AIDS.
- Trial name
- NCT00002113
- Testing
- Flucytosine, Fluconazole
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Pfizer
Meningococcal Meningitis
Comparison of Two Meningococcal ACWY Conjugate Vaccines
There is evidence of waning immunity in individuals vaccinated against meningitis C as part of the UK infant immunisation schedule.
- Trial name
- PRIME (NCT01192997)
- Testing
- Menveo, MenACWY-TT
- Where
- 3 sites in United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Public Health England
Cryptococcal Meningitis
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)
This study is designed as two sequential trials. The first is a phase I open label trial to evaluate the safety and tolerability of MAT2203.
- Trial name
- EnACT (NCT04031833)
- Testing
- MAT2203, Amphotericin B
- Where
- Uganda
- Volunteers
- 178 people
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Hepatitis B, Poliomyelitis
Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course
The study will compare the immunogenicity and the reactogenicity of INFANRIX™ HEXA and HEXAVAC™ vaccines in a 3, 5 and 11 - 12 month vaccination schedule.
- Conditions
- Hepatitis B, Poliomyelitis, Diphtheria, Acellular Pertussis
- Trial name
- NCT01457547
- Testing
- DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA), DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)
- Where
- 9 sites in Finland, Italy and 1 more
- Volunteers
- 494 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus, Poliomyelitis
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
This study is designed to evaluate the safety and immunogenicity of new formulations of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (GSK217744) when administered as a primary vaccination course to healthy infants at 2, 3 and 4…
- Conditions
- Tetanus, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type b
- Trial name
- NCT01248884
- Testing
- Infanrix hexa™, Prevenar 13®, GSK217744
- Where
- 16 sites in Dominican Republic, Finland
- Volunteers
- 721 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Cryptococcal, HIV Infections
Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal meningitis in AIDS patients. Both newly diagnosed and relapsed patients are eligible.
- Trial name
- NCT00002076
- Testing
- Fluconazole
- Where
- 3 sites in United States
- Sponsor
- Pfizer
Tuberculosis Meningitis, HIV-1-infection
Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM
LASER-TBM is a parallel group, randomized, multi-arm phase IIa trial evaluating the safety of increased dose rifampicin (RIF) plus linezolid (LZD), with or without aspirin (ASA), for the treatment of HIV-infected adults with…
- Trial name
- LASER-TBM (NCT03927313)
- Testing
- Linezolid, High dose rifampicin, Aspirin
- Where
- 4 sites in South Africa
- Volunteers
- 52 people
- Sponsor
- University of Cape Town
Central Nervous System Tuberculosis
A Retrospective Study of Treatment Patterns and Clinical Outcomes in Patients With Central Nervous System Tuberculosis
This is a retrospective clinical study to analyze the clinical characteristics, complications, and effects of different treatment options on long-term prognosis in patients with central nervous system tuberculosis.
- Trial name
- NCT06011915
- Where
- 2 sites in China
- Volunteers
- 638 people
- Sponsor
- Tongji Hospital
Meningitis, Meningococcal
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
The purpose of this study is to evaluate the immunogenicity and safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 to 5 months.
- Trial name
- NCT05252715
- Testing
- Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, Meningococcal A and C Polysaccharide Conjugate Vaccine
- Where
- 2 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Meningitis, Meningococcal
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age
MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more than 60 countries.
- Trial name
- NCT03433482
- Testing
- MenACWY liquid, MenACWY
- Where
- 49 sites in Brazil, Estonia and 7 more
- Volunteers
- 1,707 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Meningococcal Disease
Safety Surveillance of MenACWY-CRM Vaccine in Children
The purpose of this study is to summarize the occurrence of incident serious medically attended events and events of interest up to 1 year following MenACWY-CRM vaccination administered as part of routine clinical care.
- Trial name
- NCT01452438
- Testing
- MenACWY-CRM
- Where
- United States
- Volunteers
- 393 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Infection, Surgery
Topical Vancomycin for Neurosurgery Wound Prophylaxis
This study is a collaboration between New York Presbyterian (NYP)-Columbia and NYP-Cornell that seeks to evaluate the use of topical vancomycin and its reduction on surgical site infection (SSI) in neurosurgical procedures.
- Conditions
- Infection, Surgery, Nervous System Diseases
- Trial name
- Vanguard (NCT02284126)
- Testing
- Vancomycin
- Where
- United States
- Volunteers
- 1,103 people
- Sponsor
- Columbia University
General Paresis
Clinical Findings in General Paresis
This is a study of the clinical and neuroimaging of general paresis. The investigators studied six patients with general paresis.
- Trial name
- NCT00921648
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Xijing Hospital
Cryptococcal Meningitis, HIV/AIDS
Three Induction Treatments on Cryptococcal Meningitis
Three induction treatment strategies [ voriconazole +5FC vs. amphotericin deoxycholate (0.4-0.5 mg/kg/d)+5FC vs. amphotericin deoxycholate (0.7-1.0 mg/kg/d)+5FC ] for HIV-infected patients with cryptococcal meningitis were…
- Trial name
- TITOC (NCT04072640)
- Testing
- Voriconazole 200mg, amphotericin B deoxycholate (0.4-0.5mg/kg/d), Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Autoimmune Disease, Mental Disorder
Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections
Bacteria carry substances on their surface called antigens. When antigens come into contact with the right kinds of cells in the body an immune reaction is caused.
- Conditions
- Autoimmune Disease, Mental Disorder, Obsessive Compulsive Disorder, Streptococcal Infection
- Trial name
- NCT00001658
- Testing
- Amoxicillin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bacterial Meningitis
Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis
The main purpose of this trial is to test if mortality of childhood bacterial meningitis can be reduced by slow, continuous infusion of cefotaxime initially, instead of the traditional bolus administration four times daily (qid)…
- Trial name
- INFU/PARA (NCT01540838)
- Testing
- Infusion with paracetamol, Bolus without paracetamol
- Where
- Angola
- Volunteers
- 375 people
- Sponsor
- University of Helsinki
Increased Lordosis/Scoliosis, Hyporeflexia
Biomarker for Duchenne Muscular Dystrophy
International, multicenter, observational, longitudinal study to identify biomarker/s for Duchenne Muscular Dystropy (DMD) and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s.
- Conditions
- Increased Lordosis/Scoliosis, Hyporeflexia, Duchenne Muscular Dystrophy, Red-Green Color Blindness
- Trial name
- BioDuchenne (NCT02994030)
- Where
- 12 sites in Albania, Egypt and 6 more
- Volunteers
- 103 people
- Sponsor
- CENTOGENE GmbH Rostock